MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells
- 2 January 2015
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (1) , e985924
Abstract
Tumor cells have a tendency to use glucose fermentation to obtain energy instead of mitochondrial oxidative phosphorylation (OXPHOS). We demonstrated that this phenotype correlated with loss of ERK5 expression and with reduced MHC class I expression. Consequently, tumor cells could evade cytotoxic T lymphocyte (CTL)-mediated immune surveillance, but also increase their sensitivity to natural killer (NK) cells. These outcomes were evaluated using two cellular models: leukemic EL4 cells and L929 transformed fibroblasts and their derived ρ° cell lines, which lack mitochondrial DNA. We have also used a L929 cell sub-line that spontaneously lost matrix attachment (L929dt), reminiscent of metastasis generation, that also downregulated MHC-I and ERK5 expression. MHC-I expression is lower in ρ° cells than in the parental cell lines, but they were equally sensitive to CTL. On the contrary, ρ° cells were more sensitive to activated NK cells than parental cells. On the other hand, L929dt cells were resistant to CTL and NK cells, showed reduced viability when forced to perform OXPHOS, and surviving cells increased MHC-I expression and became sensitive to CTL. The present results suggest that when the reduction in MHC-I levels in tumor cells due to glycolytic metabolism is partial, the increase in sensitivity to NK cells seems to predominate. However, when tumor cells completely lose MHC-I expression, the combination of treatments that increase OXPHOS with CTL-mediated immunotherapy could be a promising therapeutic approach.Keywords
This publication has 50 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and SenescenceCell, 2012
- AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stressNature, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for ImmunoeditingClinical Cancer Research, 2009
- Up on the tightrope: natural killer cell activation and inhibitionNature Immunology, 2008
- Natural killer cell–directed therapies: moving from unexpected results to successful strategiesNature Immunology, 2008
- Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Blood, 2007
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002